Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H2 2012
SUMMARY
Global Markets Direct’s, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer). Venous Leg Ulcers (Crural ulcer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
SUMMARY
Global Markets Direct’s, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer). Venous Leg Ulcers (Crural ulcer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
- A snapshot of the global therapeutic scenario for Venous Leg Ulcers (Crural ulcer).
- A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural ulcer) Overview
Therapeutics Development
An Overview of Pipeline Products for Venous Leg Ulcers (Crural ulcer)
Venous Leg Ulcers (Crural ulcer) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Venous Leg Ulcers (Crural ulcer) Therapeutics – Products under Development by Companies
Companies Involved in Venous Leg Ulcers (Crural ulcer) Therapeutics Development
Sanofi-Aventis
RegeneRx Biopharmaceuticals, Inc.
CytoTools AG
Healthpoint, Ltd.
Glycotex, Inc.
Phage Biotechnology Corporation
FirstString Research, Inc.
CoDa Therapeutics, Inc.
Adocia
Venous Leg Ulcers (Crural ulcer) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro CI-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HP802-247 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LyphoDerm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venous Leg Ulcers (Crural ulcer) Therapeutics – Drug Profile Updates
Venous Leg Ulcers (Crural ulcer) Therapeutics – Discontinued Products
Venous Leg Ulcers (Crural ulcer) Therapeutics - Dormant Products
Venous Leg Ulcers (Crural ulcer) – Product Development Milestones
Featured News & Press Releases
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
Dec 20, 2004: RegeneRx Files With FDA For Second Phase II Clinical Trial
Jun 23, 2004: Sigma-Tau Conducts Phase II Clinical Trial In Europe With Tß4 For Venous Stasis Ulcers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Venous Leg Ulcers (Crural ulcer), H2 2012
Products under Development for Venous Leg Ulcers (Crural ulcer) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Sanofi-Aventis, H2 2012
RegeneRx Biopharmaceuticals, Inc., H2 2012
CytoTools AG, H2 2012
Healthpoint, Ltd., H2 2012
Glycotex, Inc., H2 2012
Phage Biotechnology Corporation, H2 2012
FirstString Research, Inc., H2 2012
CoDa Therapeutics, Inc., H2 2012
Adocia, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Venous Leg Ulcers (Crural ulcer) Therapeutics – Drug Profile Updates
Venous Leg Ulcers (Crural ulcer) Therapeutics – Discontinued Products
Venous Leg Ulcers (Crural ulcer) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2012
Products under Development for Venous Leg Ulcers (Crural ulcer) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural ulcer) Overview
Therapeutics Development
An Overview of Pipeline Products for Venous Leg Ulcers (Crural ulcer)
Venous Leg Ulcers (Crural ulcer) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Venous Leg Ulcers (Crural ulcer) Therapeutics – Products under Development by Companies
Companies Involved in Venous Leg Ulcers (Crural ulcer) Therapeutics Development
Sanofi-Aventis
RegeneRx Biopharmaceuticals, Inc.
CytoTools AG
Healthpoint, Ltd.
Glycotex, Inc.
Phage Biotechnology Corporation
FirstString Research, Inc.
CoDa Therapeutics, Inc.
Adocia
Venous Leg Ulcers (Crural ulcer) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro CI-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HP802-247 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LyphoDerm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venous Leg Ulcers (Crural ulcer) Therapeutics – Drug Profile Updates
Venous Leg Ulcers (Crural ulcer) Therapeutics – Discontinued Products
Venous Leg Ulcers (Crural ulcer) Therapeutics - Dormant Products
Venous Leg Ulcers (Crural ulcer) – Product Development Milestones
Featured News & Press Releases
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
Dec 20, 2004: RegeneRx Files With FDA For Second Phase II Clinical Trial
Jun 23, 2004: Sigma-Tau Conducts Phase II Clinical Trial In Europe With Tß4 For Venous Stasis Ulcers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Venous Leg Ulcers (Crural ulcer), H2 2012
Products under Development for Venous Leg Ulcers (Crural ulcer) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Sanofi-Aventis, H2 2012
RegeneRx Biopharmaceuticals, Inc., H2 2012
CytoTools AG, H2 2012
Healthpoint, Ltd., H2 2012
Glycotex, Inc., H2 2012
Phage Biotechnology Corporation, H2 2012
FirstString Research, Inc., H2 2012
CoDa Therapeutics, Inc., H2 2012
Adocia, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Venous Leg Ulcers (Crural ulcer) Therapeutics – Drug Profile Updates
Venous Leg Ulcers (Crural ulcer) Therapeutics – Discontinued Products
Venous Leg Ulcers (Crural ulcer) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2012
Products under Development for Venous Leg Ulcers (Crural ulcer) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
